Aytu begins trading today on OTCQX under the symbol "AYTU." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Aytu is on its way to becoming a leading specialty urology company with established, revenue-generating products in the areas of prostate cancer and urinary tract infection, and an expanding commercial and R&D pipeline of novel urology products," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "We are proud to welcome this fast-growing company to our family of established, investor-focused OTCQX issuers."
Josh Disbrow, Chief Executive Officer of Aytu, stated, "We are excited about qualifying for the OTCQX market less than 10 months since the formation of Aytu BioScience. Considering the company's anticipated growth outlook in the near-term through the commercialization of our first urology products, moving up to OTCQX is an appropriate next step in the company's near-term growth plan. Being traded on OTCQX will allow for greater exposure, accessibility, and liquidity from the investment community as we execute on our commercially-focused strategy of building a specialty healthcare company in the urology field."
Wyrick Robbins Yates & Ponton LLP serves as Aytu's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws. "The team at Wyrick is excited to be a part of Aytu's success," said David Mannheim, a partner at Wyrick.
Aytu is a commercial-stage specialty healthcare company focused on urological and related conditions, specifically urological cancer, urinary tract infections, male infertility and sexual dysfunction.
The company currently markets ProstaScint in the United States for the detection of prostate cancer. ProstaScint is the only FDA-approved biologic imaging agent specific to prostate cancer. It also markets Primsol, the only FDA-approved oral liquid formulation of trimethoprim. Primsol is indicated for the treatment of uncomplicated urinary tract infections.
It is also conducting clinical studies on the company's MiOXSYS diagnostic system in the assessment of male infertility. MiOXSYS measures oxidation-reduction potential (ORP) in semen and seminal plasma to detect semen abnormality in a two-minute test.
The company's most advanced therapeutic candidate is Zertane, a proprietary treatment for premature ejaculation that has the potential to be the first oral therapeutic approved in the United States for this indication. Zertane is Phase 3 ready in the U.S. with an accepted Investigational New Drug application with FDA.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the OTC Pink® Open Market. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-aytu-bioscience-to-otcqx-300192051.html
SOURCE OTC Markets Group Inc.